ATLASAkebia Therapeutics (AKBA) earnings date: Nov 5, 2026
Akebia Therapeutics (AKBA) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, before the open. Analysts expect EPS of -$0.03.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on AKBA
| Last price | $0.71 (+0.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±5.4% |
| Earnings beat history | Beat the EPS estimate in 1 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Akebia Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Akebia Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Akebia Therapeutics. You can switch it off at any time.
Alert me before AKBA reportsFree to start. Creating an account takes under a minute.
Notify me when Akebia Therapeutics reports
Track AKBA free Add Akebia Therapeutics to a free ATLAS watchlist and see its next report date in one place.
AKBA earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.03 |
| Last report | Aug 5, 2026 · Miss |
| Beat rate (last 4 reports) | 1 of 4 (25%) |
| Average EPS surprise | +4.5% |
| Average move around a report | ±15.1% (last 4) |
| Sector | Healthcare · Drug Manufacturers - Specialty & Generic |
Akebia Therapeutics earnings history: last 4 reports
Akebia Therapeutics last reported on Aug 5, 2026: EPS of -$0.03 against an estimate of -$0.02 (-50.0% surprise), a miss.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 5, 2026 | -$0.02 | -$0.03 | -50.0% | Miss | -27.7% |
| Jun 11, 2026 | -$0.33 | -$0.09 | +72.7% | Beat | +6.0% |
| May 7, 2026 | -$0.03 | -$0.03 | 0.0% | In line | -21.6% |
| Feb 23, 2026 | $0.42 | $0.40 | -4.8% | Miss | +5.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for AKBA
See the fair value, the probability range and the earnings history of Akebia Therapeutics on its ATLAS page.
Akebia Therapeutics (AKBA) stock analysisPlans from €3.99 a month.
Akebia Therapeutics earnings: frequently asked questions
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics is scheduled to report on Thursday, November 5, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for AKBA?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.03 per share (USD). Estimates can change before the report.
How often does AKBA beat earnings estimates?
Of its last 4 reports with a recorded result, Akebia Therapeutics beat the EPS estimate 1 times; the average surprise was +4.5%. Past results do not predict the next one.
How much does AKBA move around earnings?
Over its last 4 reports the stock moved an average of 15.1% (absolute, from the close before the report day to the close after it), and finished higher 2 of 4 times.
Did Akebia Therapeutics beat earnings estimates last quarter?
Akebia Therapeutics last reported on Aug 5, 2026: EPS of -$0.03 against an estimate of -$0.02 (-50.0% surprise), a miss.
How much does AKBA usually move in a day?
On a normal trading day the ATLAS model puts AKBA’s one-day range at about ±5.4%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer